Log in to save to my catalogue

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refr...

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refr...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1753437635

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patie...

Alternative Titles

Full title

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1753437635

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1753437635

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(15)00464-7

How to access this item